Treatment of Irritable Bowel Syndrome with Saccharomyces Cerevisiae

Abstract

AIM: To evaluate the effect of probiotic Saccharomyces Cerevisiae in the treatment of Irritable Bowel Syndrome in a randomized, double-blind placebo-controlled clinical trial. METHODS: A randomized, double-blind placebo-controlled clinical trial has been performed in 347 adults, diagnosed with IBS (Rome III criteria). Subjects were randomized to receive 1000 mg BID of Saccharomyces Cerevisiae daily for four-week, product 177, placebo 170. IBS symptoms (abdominal pain/discomfort, bloating/ distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily by the patients and assessed weekly by the investigator. RESULT: Improvement of Gastrointestinal symptoms was significantly higher in the product group, compared to the placebo, on (abdominal pain/discomfort, bloating/distension, bowel movement difficulty, with stool modification), p-value < 0.001 in the treated group, and the ratio between groups (130 vs. 47), (73.4% vs. 27.64%). CONCLUSION: Saccharomyces Cerevisiae significantly improves irritable bowel syndrome symptoms and is well tolerated.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

“…The literature search identified 4111 citations, of which 46 appeared to be relevant, and 17 were eligible and were incorporated into this guideline. [164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180] Fourteen of these were used to update meta-analyses. [164][165][166][167][168][169][170][171][172][173][174][175][176][177] Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81).…”

“…[164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180] Fourteen of these were used to update meta-analyses. [164][165][166][167][168][169][170][171][172][173][174][175][176][177] Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81). Of these 14 studies, 2 compared linaclotide with placebo, 164 165 and were used to update a previous network meta-analysis, 155 8 compared various probiotics with placebo, [166][167][168][169][170][171][172][173] and were used to update an existing trial-based meta-analysis 158 and 4 were RCTs of a low FODMAP diet, [174][175][176][177] and again were used to update a prior trial-based meta-analysis.…”

“…[164][165][166][167][168][169][170][171][172][173][174][175][176][177] Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81). Of these 14 studies, 2 compared linaclotide with placebo, 164 165 and were used to update a previous network meta-analysis, 155 8 compared various probiotics with placebo, [166][167][168][169][170][171][172][173] and were used to update an existing trial-based meta-analysis 158 and 4 were RCTs of a low FODMAP diet, [174][175][176][177] and again were used to update a prior trial-based meta-analysis. 161 The remaining 3 RCTs were an 8-week trial of bimodal release ondansetron in IBS-D, 178 and 2 phase II trials of minesapride 179 180 a novel 5-HT 4 receptor agonist.…”

“…216 The theory that this might, in part, be involved in pathophysiology has led to interest in whether probiotics, which are live or attenuated microorganisms that may have beneficial effects in humans, can be used to alter the microbiome, improving symptoms. We updated a prior meta-analysis of 37 RCTs, 158 incorporating data from 8 new trials [166][167][168][169][170][171][172][173] and randomising 6352 patients. Subgroup analyses according to type of probiotic used (where more than one trial of a particular group of probiotics was conducted) demonstrated significant effects on global symptoms or abdominal pain for combinations of probiotics (RR 0.79; 95% CI 0.70 to 0.89), Lactobacillus (RR 0.75; 95% CI 0.60 to 0.94), Bifidobacterium (RR 0.80; 95% CI 0.70 to 0.91) and Escherichia (RR 0.86; 95% CI 0.79 to 0.93) (online supplemental figure 3).…”